The effects of the intestinal glucosidase inhibitor Bay m 1099 (Miglitol) on glycemic status of obese rats
1989
DeBouno, J.F. | Michaelis, O.E. | Tulp, O.L.
An experimental pharmacological intestinal glucosidase inhibitor, Bay m 1099 (Miglitol), was used to investigate the effects of delayed carbohydrate absorption on parameters of glycemic status in a congenic rat strain that exhibits characteristics of early onset obesity and impaired glucose tolerance (IGT), LA/N-cp (LA-corpulent). Male, lean and obese 8 week old rats were fed diets ad libitum containing 54% sucrose, 20% protein, 16% fat plus other essential nutrients with and without Bay m 1099 (15 mg/100g diet) for 7 weeks. Periodic measures of body weight, food intake, glycemic status including daily postprandial glycosuria, and oral glucose tolerance testing (OGTT), and glycosylated hemoglobin content were performed. Drug tre atment was without effect on food intake or body weight, but resulted in improvements in several insulin-dependent metabolic parameters indicative of glycemic status including prominent reduction of glycosuria, gradual improvement in fasting insulin levels with partial normalization of OGTT in obese animals and in lowered % glycosylated hemoglobin content in animals of both phenotypes. These results are consistent with improved insulin sensitivity and post-prandial glycemic following drug treatment, and suggest that Bay m 1099 may be a useful dietary adjunct in the treatment of obesity, type IV hyperlipoproteinemia, and other disorders associated with the insulin resistant state.
显示更多 [+] 显示较少 [-]